DTx EAST 2019

DTx EAST 2019

September 24 - 26 | Boston, MA

DEFINING HOW DIGITAL THERAPEUTICS ARE GOING TO INTEGRATE INTO HEALTHCARE

Registration Agenda

Partners

Premium Partner
Klick
Knowledge Partner
Knowledge Partner

BrightInsight, a Flex Company, provides the leading global regulated digital health platform for biopharma and medtech. Our medical-grade Internet of Things (IoT) platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement.

The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with security, privacy and regulatory requirements.

Knowledge Partner

Ieso Digital Health is a biotechnology company whose mission it is to harness advanced technology and clinical science to deepen the understanding of the causes, symptoms and treatments of mental health problems.

By delivering psychological care to patients using the Ieso online therapy platform, a combination of data science, and advanced analytics can be used to develop digital therapeutics, education and training, and AI tools, to change the way mental healthcare is delivered across the world.

Ieso’s employees are dedicated to building a new paradigm in mental health science; building a complete understanding of the root causes of mental health conditions and developing interventions that will address the personal, societal and economic impacts of mental illness, paving the way for a world where everyone has access to the help they need, when they need it.

Knowledge Partner

TopLine Power® is what Simon-Kucher is all about. We help clients grow revenue through optimization of strategy, pricing, marketing, and sales across industries.

We are a thought leader in these topics at the intersection of digitalization and life sciences, positioning our clients thrive in the healthcare industry of the future.

RB Health
Biorasi
Summit Partner
Summit Partner

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.

Supporters
Supporter

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes.

Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Supporter
Supporter

Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.

Supporter

JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.

We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.

Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.

Supporter

Sanofi Digital Medicine, under the Chief Medical Office, improves patient outcomes through the development of innovative technology-driven solutions that when combined with drugs, improve treatment efficacy, safety, adherence and overall experience.

Key Numbers
300
Attendees

Join over 300 senior leaders from DTx companies, pharma, investors, payers and HCP’s at the meeting point of the digital therapeutics industry.

55+
Expert speakers

Hear from the pioneers and decision-makers from across healthcare as they decipher the leading opportunities for digital therapeutics integration.

15
Hours of networking

Brand new networking-specific sessions including speed networking, dedicated 1-2-1 meeting time and more will provide more opportunities for you to meet the experts and future collaborators.

The DTx Series is my go-to place for staying up-to-date and meeting all of the key players in this promising new digital health category.

Bozidar Jovecevic, VP, Global Head of Digital Therapeutics, Sanofi

I am excited to attend DTx for the fourth time. Whether as a presenter or part of the audience, I learn so much from other Digital Therapeutic executives and attendees about topics ranging from clinical trials to commercialization and everything in between!

Debra Reisenthel, Founding CEO, Palo Alto Health Sciences

I have been to the two editions of DTx West and I’m looking forward to attending DTx East this year. The conference brings together key leaders from across the digital health space to discuss new ideas and ongoing trends that are useful takeaways to bring back to my team.

Pablo Pantaleoni, VP & General Manager, Headspace Health

2019 Speakers

Sukanya Soderland
Sukanya Soderland
Chief Strategy Officer
Blue Cross Blue Shield Massachusetts
Sukanya Soderland
Chief Strategy Officer
Blue Cross Blue Shield Massachusetts
Bozidar Jovecevic
Bozidar Jovecevic
VP, Global Head of Digital Therapeutics
Sanofi
Bozidar Jovecevic
VP, Global Head of Digital Therapeutics
Sanofi
Elli Kaplan
Elli Kaplan
CEO
Neurotrack
Elli Kaplan
CEO
Neurotrack

Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.

Zack Lynch
Zack Lynch
Managing Partner
JAZZ Venture Partners
Zack Lynch
Managing Partner
JAZZ Venture Partners

Zack Lynch is a Managing Partner and co-founder of JAZZ Venture Partners, a San Francisco-based early stage venture capital firm focused on investing in human performance technology. He is an entrepreneur and futurist who brings a rich understanding of the forces driving the convergence of digital technologies and neuroscience and how new products and services are emerging to unlock human potential across health, wellness, learning, training, sports, enterprise and entertainment. He is the author of the best selling book The Neuro Revolution: How Brain Science Is Changing our World (St. Martin’s Press) which takes a 50 year view on how neuroscience will transform human society. Zack loves to snow board and spend time with his wife and kids.

Adam Kaufman
Adam Kaufman
CEO
Canary Health
Adam Kaufman
CEO
Canary Health

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Crystal Broj
Crystal Broj
Chief Technology & Digital Officer
American Association of Diabetes Educators
Crystal Broj
Chief Technology & Digital Officer
American Association of Diabetes Educators
Pavan Choski
Pavan Choski
Investment Associate
Arkitekt Ventures
Pavan Choski
Investment Associate
Arkitekt Ventures

Pavan Choksi is an Investment Associate at Arkitekt Ventures, an early stage healthcare venture fund based in New York City that specializes in investments in novel models of healthcare delivery including digital therapeutics and applications of frontier technology such as artificial intelligence, augmented reality, genomics, and brain machine interfaces to medicine.

Prior to Arkitekt, he was the first employee and Vice President of Corporate Development for Rx.Health, a venture-backed Mount Sinai Health System spin-off commercializing a novel Digital Medicine prescription and delivery platform. As an active member of the digital health ecosystem, he serves as Strategic Advisor to the Digital Therapeutics Alliance and NODE Health.

Erez Raphael
Erez Raphael
CEO
Dario Health
Erez Raphael
CEO
Dario Health

Passionate about building great products with great user experience! I’m also passionate about Digital Health and value-driven healthcare.

I’m lucky spending all my time bringing this world together as the CEO of DarioHealth Corp. (NASDAQ: DRIO) a leading global digital therapeutics company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by accumulated data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way.

Jo Masterson
Jo Masterson
Chief Product Officer
2Morrow, Inc.
Jo Masterson
Chief Product Officer
2Morrow, Inc.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.

Abhishek Shah
Abhishek Shah
Co-Founder & CEO
Wellthy Therapeutics
Abhishek Shah
Co-Founder & CEO
Wellthy Therapeutics
Acacia Parks
Acacia Parks
Chief Scientist
Happify Health
Acacia Parks
Chief Scientist
Happify Health

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Jeffrey Abraham
Jeffrey Abraham
VP, Market Access & Trade
Akili Interactive
Jeffrey Abraham
VP, Market Access & Trade
Akili Interactive

Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.

Timothy Aungst
Timothy Aungst
Associate Professor, Pharmacy Practice
MCPHS University
Timothy Aungst
Associate Professor, Pharmacy Practice
MCPHS University

Timothy Aungst, PharmD is an Associate Professor of Pharmacy Practice at MCPHS University, Worcester, MA. He graduated from Wilkes University Nesbitt School of Pharmacy, Wilkes-Barre, PA, in 2011. Afterwards, he pursued a PGY-1 Pharmacy Practice Residency at St. Luke’s University Hospital, Bethlehem, PA, with an emphasis on Internal Medicine, Cardiology, and Geriatric Care. He then completed a fellowship program focused on geriatic care, Medicare/Medicaid and drug management, and academia. While completing his post-grad training, he started writing for multiple companies on mHealth and Digital Health, with a focus on mobile apps. Since then, he has conducted research on digital health technologies in the pharmacy space and published in multiple peer review journals and spoken at multiple venues on the topic. He hopes to inspire the pharmacy profession to further integrate digital health into patient care and raise awareness on the future possibilities posed in the coming decades.

Yvonne Yu-Feng Chan
Yvonne Yu-Feng Chan
Director, Center for Digital Health
Icahn School of Medicine at Mount Sinai
Yvonne Yu-Feng Chan
Director, Center for Digital Health
Icahn School of Medicine at Mount Sinai

Yvonne Yu-Feng Chan, MD, PhD, FACEP is the Director of the Center for Digital Health at the Icahn Institute of Mount Sinai. She is a national leader in digital medicine research and a board-certified Emergency physician. The mission of her Digital Health Center is to drive large-scale participation of patients in biomedical research and clinical care, by leveraging the latest digital technology and advanced analytic techniques to uncover novel insights and actionable results.

Dan Henderson
Dan Henderson
Primary Care Physician
Massachusetts General Hospital
Dan Henderson
Primary Care Physician
Massachusetts General Hospital
Mette Dhyrberg
Mette Dhyrberg
Founder & Chief Executive Officer
Mymee
Mette Dhyrberg
Founder & Chief Executive Officer
Mymee
Dannielle Sherrets
Dannielle Sherrets
Director, Health Innovations & Special Projects
National Business Group on Health
Dannielle Sherrets
Director, Health Innovations & Special Projects
National Business Group on Health
Debra Reisenthel
Debra Reisenthel
Founding CEO
Palo Alto Health Sciences
Debra Reisenthel
Founding CEO
Palo Alto Health Sciences

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.

Pierre Leurent
Pierre Leurent
CEO
Voluntis
Pierre Leurent
CEO
Voluntis

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

Joris van Dam
Joris van Dam
Executive Director, Head of Digital Therapeutics
Novartis
Joris van Dam
Executive Director, Head of Digital Therapeutics
Novartis
Andre Heeg
Andre Heeg
Head of Digital
Sandoz
Andre Heeg
Head of Digital
Sandoz

André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.

André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.

Peter Hames
Peter Hames
Co-Founder & CEO
Big Health
Peter Hames
Co-Founder & CEO
Big Health
Andy Blackwell
Andy Blackwell
Chief Scientific Officer
Ieso Digital Health
Andy Blackwell
Chief Scientific Officer
Ieso Digital Health
Chihiro Hosoya
Chihiro Hosoya
BD / VC Head, Rx+ Business Accelerator
Astellas Venture Management
Chihiro Hosoya
BD / VC Head, Rx+ Business Accelerator
Astellas Venture Management

Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas. Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business. In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device. Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business. She received an MSc from Waseda University and an MBA from Tsukuba University.

Bakul Patel
Bakul Patel
Director, Division of Digital Health
FDA
Bakul Patel
Director, Division of Digital Health
FDA

Bakul Patel is Director for Division of Digital Health, at the Center for Devices and Radiological Health (CDRH), at the Food and Drug Administration (FDA). Mr. Patel is responsible for providing leadership, development, implementing, execution, management and setting strategic direction and regulatory policy and coordinate scientific efforts for digital health, software and emerging technologies.

This includes responsibilities in leading the development on policies for mobile health, health information technology, cyber security, medical device interoperability, and medical device software.

Mr. Patel also led the creation of the globally harmonized regulatory framework for “software as a medical device” (SaMD) at the International Medical Device Regulators Forum (IMDRF). The concepts, principles and vocabulary created in harmonized regulatory framework has been used as a foundation in the European union, Japan, Canada, Brazil, Australia and USFDA.
Mr. Patel is the FDA liaison between the Federal Communications Commission (FCC) and the Office of the National Coordinator (ONC).

Mr. Patel is currently leading the effort for the agency in developing an innovative software precertification program in collaboration with all stakeholders to reimagine a regulatory approach for Digital health that that aims for patients and providers to have timely access to safe and effective digital health products.
Prior to joining FDA, Mr. Patel held key leadership positions in the telecommunications industry, semiconductor capital equipment industry, wireless industry and information technology industry. His experience includes Lean Six Sigma, creating long and short- term strategy, influencing organizational change, modernizing government systems, and delivering high technology products and services in fast-paced, technology-intensive organizations. Mr. Patel earned an MS in Electronic Systems Engineering from the University of Regina, Canada, and an MBA in International Business from The Johns Hopkins University.

Shaan Gandhi
Shaan Gandhi
Principal
Longwood Fund
Shaan Gandhi
Principal
Longwood Fund

Dr. Gandhi is a Principal at Longwood Fund, where he creates and invests in science-based companies that develop novel solutions for major medical problems. Prior to Longwood, he was an attending hospitalist at the Massachusetts General Hospital, where he also trained as a resident physician in internal medicine. He previously held an investing role at Excel Venture Management, where he evaluated early-stage biopharmaceutical and healthcare IT investments, an operating role at Wellable, where he helped to build a mobile corporate wellness startup as its Chief Medical Officer, and consulting roles at McKinsey & Company and the TriZetto Corporation. He holds an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, where he was a Baker Scholar, a D.Phil. in medical oncology from the University of Oxford where he was a Rhodes Scholar, and a B.S. with honors in biochemistry from Case Western Reserve University. He is the Secretary/Treasurer of the Suffolk District Medical Society, the professional medical society of Boston, and is a past trustee of the Massachusetts Medical Society and Boston Medical Library.

David Klein
David Klein
Co-Founder & CEO
Click Therapeutics
David Klein
Co-Founder & CEO
Click Therapeutics

Former Managing Director at Opus Point Partners which created, financed, & operated 10+ science companies including Cougar Biotechnology (CGRB), Chelsea Therapeutics (CHTP), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Ziopharm Oncology (ZIOP)
Co-Founder & Owner at Klein Sun Gallery, America’s leading Chinese contemporary art gallery
Guest Lecturer, Biotechnology Program at Columbia University & 17+ years life science industry experience
Former Senior Consultant at Pfizer & Strategic Advisor at publicly traded & privately held life science companies
B.A., Brandeis University

David Amor
David Amor
Vice President
Pear Therapeutics
David Amor
Vice President
Pear Therapeutics

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Matthew Tucker
Matthew Tucker
Executive Director, Strategy & Transformation
Highmark Health
Matthew Tucker
Executive Director, Strategy & Transformation
Highmark Health

Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.

Megan Coder
Megan Coder
Executive Director
Digital Therapeutics Alliance
Megan Coder
Executive Director
Digital Therapeutics Alliance

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

 Ed Cox
Ed Cox
CEO
Dthera Sciences
Ed Cox
CEO
Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Pablo Pantaleoni
Pablo Pantaleoni
Vice President & General Manager
Headspace
Pablo Pantaleoni
Vice President & General Manager
Headspace
Eddie Martucci
Eddie Martucci
Co-Founder & CEO
Akili Interactive
Eddie Martucci
Co-Founder & CEO
Akili Interactive

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Jim Harper
Jim Harper
Co-Founder & Chief Operating Officer
Sonde Health
Jim Harper
Co-Founder & Chief Operating Officer
Sonde Health

Jim has over 25 years of experience harnessing innovative technologies to solve important biological measurement problems.

Shortly after joining PureTech Health in 2015, he co-founded Sonde Health to provide high-frequency clinical-grade health measurements of health and disease using voice analysis on devices that people already own. He was previously with MIT Lincoln Laboratory where he worked for 15 years to help grow new biotechnology and bioengineering capabilities and teams.

Dr. Harper received his BS in biochemistry from Furman University, his PhD in biochemistry from MIT, and was a postdoctoral research fellow at Harvard Medical School in the Center for Neurologic Diseases.

Spencer Jones
Spencer Jones
Vice President, Global Medical Affairs
Sandoz
Spencer Jones
Vice President, Global Medical Affairs
Sandoz
Mark Bini
Mark Bini
Vice President, New Solutions
Express Scripts
Mark Bini
Vice President, New Solutions
Express Scripts

Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for Express Scripts’ suite of digital therapeutic solutions that includes remote monitoring solutions for diabetes, asthma, and medication non-adherence. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.

Charlie Gross
Charlie Gross
Vice President
Anthem
Charlie Gross
Vice President
Anthem
Owen McCarthy
Owen McCarthy
Co-Founder & President
MedRhythms
Owen McCarthy
Co-Founder & President
MedRhythms

Owen is the co-founder and President of MedRhythms Inc., which he intends to lead with compassion and a commitment to excellence. He is determined to provide patients across the globe with the services necessary to recover their walking ability and regain their independence. Owen started MedRhythms as an experienced entrepreneur with a MBA degree from Harvard Business School.

Anil Jina
Anil Jina
Chief Medical Officer
Akili Interactive
Anil Jina
Chief Medical Officer
Akili Interactive

Anil is a physician executive based in the Boston area and has over 20 years of global healthcare and biopharmaceutical experience. He studied medicine in Ireland and worked clinically in the Irish healthcare system before moving to the biopharmaceutical industry where he has held roles of increasing responsibility across different companies, different therapeutic areas and different geographies.

Anil’s interest in developing world healthcare started while he was studying medicine at the Royal College of Surgeons in Ireland, where he raised money to purchase medical supplies for a rural health clinic in Tanzania, East Africa, and delivered them personally as well as working in the clinic for 3 months. More recently he has been instrumental in establishing a charitable access program to rare disease medicines which is now operating across 10 countries.

Patricia Simon
Patricia Simon
Director, Innovation Impact
Yale School of Medicine
Patricia Simon
Director, Innovation Impact
Yale School of Medicine
Jennifer White
Jennifer White
Senior Vice President, Strategic Partnerships
Klick Consulting
Jennifer White
Senior Vice President, Strategic Partnerships
Klick Consulting
Alex Waldron
Alex Waldron
Chief Strategy Officer
Pear Therapeutics
Alex Waldron
Chief Strategy Officer
Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Michael Lieberman, PhD
Michael Lieberman, PhD
Senior Vice President, Medical Sciences
Klick Consulting
Michael Lieberman, PhD
Senior Vice President, Medical Sciences
Klick Consulting
Chuck Gammal
Chuck Gammal
Partner
Simon-Kucher & Partners
Chuck Gammal
Partner
Simon-Kucher & Partners

Chuck Gammal is a Partner within the Life Sciences division at Simon-Kucher. Chuck’s focus is on helping clients navigate the challenges of developing sustainable digital businesses.

Specifically, Chuck helps digital health, medical technology, and pharmaceutical clients identify and deploy the optimal commercial model to monetize innovation.

Brent Vaughan
Brent Vaughan
Chief Executive Officer
Cognoa
Brent Vaughan
Chief Executive Officer
Cognoa

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

Ed Cox
Ed Cox
Chief Executive Officer
Dthera Sciences
Ed Cox
Chief Executive Officer
Dthera Sciences

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Kenichiro Nishii
Kenichiro Nishii
Lead, Regulatory Affairs & Business Development
CureApp
Kenichiro Nishii
Lead, Regulatory Affairs & Business Development
CureApp

Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.

With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.

In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.

Jennifer White
Jennifer White
Senior Vice President, Strategic Partnerships
Klick Consulting
Jennifer White
Senior Vice President, Strategic Partnerships
Klick Consulting

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Anand Iyer
Anand Iyer
Chief Strategy Officer
Welldoc
Anand Iyer
Chief Strategy Officer
Welldoc

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Kristine Seymour
Kristine Seymour
Partner
Michael Best Strategies
Kristine Seymour
Partner
Michael Best Strategies

Kristine leads the National Healthcare Practice at Michael Best Strategies. Previously, she was the RVP of Market Development for Humana. Kristine works with healthcare start-ups focusing on tactical execution in the commercialization of their company with a focus on revenue and growth. She leverages her expansive connections in the C-suite of national payers, providers, governmental agencies and employer coalitions to bring innovation to the healthcare ecosystem while focusing on the ROI.

Georgia Misti
Georgia Misti
Senior Director
Frontier Business, Sunovion Pharmaceuticals
Georgia Misti
Senior Director
Frontier Business, Sunovion Pharmaceuticals
Anton Decker
Anton Decker
President, Health Innovation
Bon Secours Mercy
Anton Decker
President, Health Innovation
Bon Secours Mercy

Dr. G. Anton Decker is the President, Health Innovation, for Bon Secours Mercy Health, an $8 billion net revenue multistate health system of 43 hospitals and 57,000employees, including 2,100 physicians and advance practice clinicians. Reporting to the CEO for Bon Secours Mercy Health, he develops innovative partnerships with a focus on data and digital innovation. Previously he was the Chief Clinical Officer for Mercy Health, a $4.5 billion net revenue health system based out of<br />
Ohio and Kentucky with system-wide oversight of clinical operations and valuebased care. He has served as the president of Mercy Health Physicians, a multispecialty medical group of over 1300 providers. Prior to Mercy Health he was the chief medical officer and chairman of the board for Banner Medical Group, Banner Health’s employed physician group of over 1300 providers located in Arizona, Alaska, Colorado, Nebraska, Nevada and Wyoming. He was the chairman of the board for Banner Health Network, Banner’s Accountable Care Organization with a network of over 2500 providers in Arizona.

Tammi Grumski
Tammi Grumski
Diabetes Program Director
UPMC Health Plan
Tammi Grumski
Diabetes Program Director
UPMC Health Plan
Scott DeMario
Scott DeMario
HR Benefits Consultant
CUNA Mutual Group
Scott DeMario
HR Benefits Consultant
CUNA Mutual Group
Vincent Hennemand
Vincent Hennemand
Senior Vice President, Strategy, Corporate & Business Development
Akili Interactive
Vincent Hennemand
Senior Vice President, Strategy, Corporate & Business Development
Akili Interactive

At Akili Interactive Labs Mr. Hennemand is currently SVP of Strategy, Corporate & Business Development, Vincent is also leading the Immuno- Inflammation Therapeutic Unit. Prior his tenure at Akili, Vincent was previously VP Corporate Development and Operations at PureTech Health, the founding institution of Akili Therapeutic Labs. Vincent spent a decade in Pharma at Sanofi Genzyme during which he had the opportunity to hold several positions from R&D, General Management, Manufacturing and Corporate Venture (SGBV) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio and Portal Instruments. He holds an Msc in Engineering from Ecole Nationale Superieure Arts et Metiers in France, an Msc in Bioengineering from Georgia Tech, and an MBA from MIT where he received a Martin Trust Center scholarship as Healthcare Sector Practice Leader for the Institute.

Dave Evendon-Challis
Dave Evendon-Challis
Vice President, Innovation
RB
Dave Evendon-Challis
Vice President, Innovation
RB

Dave’s passion is for creating and scaling health innovations for existing and new brands. He joined RB, a leading consumer health & hygiene business, in 2011 where he developed and launched RB’s industry-leading sustainability strategy, betterbusiness. In 2013 his remit was expanded to incorporate the company’s innovation programme. He is currently accountable for health innovation across the infant & child nutrition, wellness, OTC and personal hygiene categories – with a focus on disruptive innovation, digital & partnerships. Before joining RB he was Head of Consultancy at Salterbaxter MSL. Prior to this, he was Head of Sustainability & Public Affairs for Kimberly-Clark EMEA . Dave has a MA in Biological Sciences from Oxford University and lives in London.

Wayne Bowden
Wayne Bowden
Vice President - Program Development
Biorasi
Wayne Bowden
Vice President - Program Development
Biorasi

Wayne Bowden is the Vice President of Program Development at Biorasi. Wayne oversees the design, development and optimization of Sponsor projects and serves as project director on various programs including: neurology, nephrology, rare disease, and digital therapeutics, in addition to Biorasi’s many clinical trial rescues.

Kal Patel, MD
Kal Patel, MD
CEO & Co-founder
BrightInsight, a Flex Company
Kal Patel, MD
CEO & Co-founder
BrightInsight, a Flex Company

Kal Patel has over 20 years of experience in pharma, medtech and regulated digital health. Prior to joining BrightInsight, he was Chief Commercial Officer for Doctor on Demand, now the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.

Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of digital products in connected devices, advanced algorithms/decision making and next-generation marketing, where he launched multiple regulated devices. Kal also serves as a Senior Advisor in Digital Health to the Boston Consulting Group and various digital health startups

Tami Smith
Tami Smith
Head of Medical Affairs
Pear Therapeutics
Tami Smith
Head of Medical Affairs
Pear Therapeutics

Tami is a Medical Affairs professional with extensive experience launching game-changing therapeutics.
She currently serves as Head of Medical Affairs for Pear Therapeutics, the industry leader in digital therapeutics, and developers of the first FDA-authorized prescription digital therapeutics (PDTs). Tami has also led the Medical team for SSI Strategy, a boutique biopharma consulting firm that specializes in early-stage, innovative companies with industry-leading technologies. Tami led Medical Affairs at Spark Therapeutics, building the organization from the ground up to launch the first gene therapy for a genetic disorder in the U.S. She was previously Sr. Vice President of Global Medical Affairs for Shire Pharmaceuticals, and before that, held increasing levels of responsibility within medical affairs at Forest Laboratories and Allergan. She has also been an investment banking analyst with Bankers Trust Company. Tami received her MD from Columbia University College of Physicians and Surgeons, and her BA from Cornell University.

Sarah Jackson
Sarah Jackson
Chief of Staff
Click Therapeutics
Sarah Jackson
Chief of Staff
Click Therapeutics

Sarah Jackson is Chief of Staff at Click Therapeutics, where she operates across business development, alliance management and strategy. In her role, Sarah actively seeks partnership and licensing opportunities, supports deal execution, and manages collaboration relationships and operations. Sarah holds a B.A. cum laude in Cognitive Neuroscience and Evolutionary Psychology from Harvard College.

Omri Shor
Omri Shor
Chief Executive Officer
Medisafe
Omri Shor
Chief Executive Officer
Medisafe

Omri is the CEO & co-founder of Medisafe. In 2012 he founded Medisafe after his diabetic father accidentally double-dosed on insulin. Tapping into his considerable entrepreneurship experience, Omri successfully grew Medisafe into the leading medication management platform with over 5M users worldwide partnering with global pharma clients to develop digital health programs.

Joel Sangerman
Joel Sangerman
Chief Commercial Officer
Click Therapeutics
Joel Sangerman
Chief Commercial Officer
Click Therapeutics

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.
For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.
While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.
Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Cris de Luca
Cris de Luca
Senior Director, Global Head of Digital Innovation
Johnson & Johnson
Cris de Luca
Senior Director, Global Head of Digital Innovation
Johnson & Johnson

Cris De Luca is currently the Global Director of Digital Innovation for Johnson & Johnson Innovation, based in Cambridge, Massachusetts. He holds primary digital and data responsibilities, translating hi-tech external opportunities throughout J&J’s Innovation Centers, JLABS incubators and JJDC corporate ventures across the Pharma, Consumer and Medical Device businesses.
De Luca formerly led emerging technology programs within research informatics at Novartis Institutes for BioMedical Research. With entrepreneurial DNA, Cris is well recognized for his role in the innovation economy since Co-Founding one of the largest startup venture pitch competitions in the U.S called Ultra Light Startups, accelerating hundreds of companies in Boston, New York City and Silicon Valley.
Cris serves on the advisory boards of SXSW Health and VOICE Summit by Amazon Alexa. He was recognized as a 40 Under 40 awardee by the Boston Business Journal and Top 40 Healthcare Transformer by MM&M Magazine.

Sharif Taraman
Sharif Taraman
Chief Medical Officer
Cognoa
Sharif Taraman
Chief Medical Officer
Cognoa

Sharief Taraman, M.D. is the Chief Medical Officer at Cognoa, Inc., a Silicon Valley based startup that develops artificial intelligence-based digital diagnostics and personalized therapeutics that provide accurate, earlier diagnoses and more effective treatments to improve outcomes and lower behavioral healthcare costs. He is a Magna Cum Laude graduate of the University of Michigan having majored in Biochemistry. He completed his medical education at Wayne State University School of Medicine in 2006 and went on to complete residency training in Pediatrics and Pediatric Neurology at the Children’s Hospital of Michigan. Dr. Taraman is dual board certified in Neurology with special qualifications in child neurology from the American Board of Psychiatry and Neurology and in Clinical Informatics from the American Board of Preventative Medicine. He remains clinically active as the Division Chief of the CHOC Children’s Specialists Pediatric Neurology Division and a Health Sciences Associate Clinical Professor at UC Irvine School of Medicine. Dr. Taraman is active in the community as a board member of the AAP Orange County Chapter, Irvine Unified School District Medical Advisory Board, and volunteering for Girl Scouts of Orange County and the Capistrano Unified School District.

Carlos Rodarte
Carlos Rodarte
SVP, Life Sciences Strategy & Business Development
Health Catalyst, Inc.
Carlos Rodarte
SVP, Life Sciences Strategy & Business Development
Health Catalyst, Inc.

Carlos Rodarte is a systems thinker and business innovator, committed to enabling individuals to discover how their behaviors, biology and environment impact health outcomes. As SVP, Life Sciences Strategy & Business Development at Health Catalyst, Inc., he is helping shape the life sciences industry to become more patient-centered, and outcomes-focused.

Summit Workshops

  • Digital Therapeutics 101: The Fundamentals of the Industry
  • Hands-on with Digital Therapeutics Regulation
Digital Therapeutics 101: The Fundamentals of the Industry
Workshop Leaders

Vincent Hennemand, Senior Vice President, Strategy, Corporate & Business Development, Akili Interactive
Sarah Jackson, Chief of Staff, Click Therapeutics
Owen McCarthy, Co-Founder & President, MedRhythms

9:00am
Presentation: What does the Digital Therapeutics Industry Look like Today?
  • How has the digital therapeutics industry got to this point in its history?
  • What are the current definitions and main sectors involved in digital therapeutic development and adoption?
9:30am
Breakout Discussions

Splitting into smaller working groups, each group will discuss their current views on digital therapeutics, as well as their views on the fundamentals of the industry.

10:30am
Refreshment Break
11:00am
Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.

Leave this workshop with:
  • A clear understanding of the defining characteristics of a digital therapeutics and the sub-categories emerging
  • A deeper understanding of the leading routes to markets and partnership models for digital therapeutic commercialization
  • Up-to-date information on where digital therapeutics are already having a significant impact in healthcare
  • A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit.
  • Your questions answered by industry leading experts and your peers
12:00pm
End of Workshop
Hands-on with Digital Therapeutics Regulation
Workshop Leaders

David Amor, Vice President, Quality & Regulatory Affairs, Pear Therapeutics

Kenichiro Nishii, Lead, Regulatory Affairs & Business Development, CureApp

1:00pm
Presentation: What does the Current Digital Health Regulatory Landscape Look Like?
  • What have been the crucial advancements for digital health regulation? 
  • In relation to Digital Therapeutics, what are we anticipating the next updates in regulation to entail?
  • How are OUS regulators addressing digital therapeutics?
1:30pm
Breakout Discussions

Splitting into smaller working groups, each group will discuss the crucial sub-topics of digital health regulation, as they relate to digital therapeutics specifically…

2:30pm
Refreshment Break
3:00pm
Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.

Leave this workshop with:
  • A clear understanding of the current digital health regulatory landscape
  • A deeper understanding of how regulation is impacting digital therapeutics
  • Up-to-date information on what we are anticipating the next series of updates from regulators to look like
  • A stronger appreciation for the more emerging topics of regulation, such as AI and real-time data analysis
  • Takeaway lessons learned that relate to the level of regulation required for your product(s)/work.
4:00pm
End of Workshop

Summit Agenda

  • Day 1: September 24th
  • Day 2: September 25th
  • Day 3: September 26th
Day 1: September 24th
Registration & Networking Evening
4:30pm
Registration

Registration is open for all conference attendees ahead of the networking evening.

DTx Networking

Networking is an integral part of the DTx Series, which is why there is now more time solely dedicated to it.

Utilizing a variety of formats, attendees will be able to make dozens of new connections, meet industry leaders and catch-up with old friends. Immerse yourselves in the digital therapeutics community!

5:30pm
Speed Networking

The goal of this session is to meet with as many people as possible in just 40 minutes.
Introduce yourself to each person around your table, swap business cards and plan to meet up later on.
It’s all about the quantity of connections at this stage!

6:10pm
1-2-1 Meetings

Use this dedicated meeting time to catch up with old friends and new connections you have just made or planned to meet up with during the event.

Space will be set aside for more private conversations, as well as more organic networking to ensure that you meet everyone you want.

7:00pm
Networking Drinks

After an intense couple of hours of networking, unwind with your peers over a drink or two!

Download Agenda
Day 2: September 25th
8.00am
Breakfast & Networking
9.00am
Chair’s Opening Remarks & Setting the Scene

Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive

Digital Therapeutics: Going Beyond the Headlines
9:15am
Presentation – Digital Health Regulation, Pre-Cert Program as they Relate to Digital Therapeutics

Bakul Patel, Director, Division of Digital Health, FDA

9:45am
Keynote Panel – What is Keeping you up at Night about Digital Therapeutics?

Megan Coder, Executive Director, Digital Therapeutics Alliance
David Klein, Co-Founder & Chief Executive Officer, Click Therapeutics
Eddie Martucci, Co-Founder & Chief Executive Officer, Akili Interactive
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Chuck Gammal, Partner, Simon-Kucher & Partners

10:45am
Morning Refreshments & Networking
Day 2 will now split into two tracks
Track 1

Routes to Market for Digital Therapeutics

Chair: Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive

11:30am
Presentation – How to Partner with Self-Insured Employers

Dannielle Sherrets, Director, Health Innovations & Special Projects, National Business Group on Health

11:55am
Presentation – From DTx Product to Global Brand – Partnering to Scale Your Innovation

Dave Evendon-Challis, Vice President, Innovation, RB

12:20pm
Presentation – Breaking Down Silos: Why Digital Health Solutions Need the Ecosystem to Succeed

Kal Patel, MD, CEO & Co-founder, BrightInsight, a Flex Company

Track 2

Showcases & Crucial Considerations

Chair: Ed Cox, Chief Executive Officer, Dthera Sciences

11:30am
Presentation – Forging Hope Against in the Fight Against Alzheimer’s Disease through Digital Therapeutics

Elli Kaplan, Chief Executive Officer, Neurotrack

11:55pm
Presentation by Biorasi

Wayne Bowden, Vice President, Program Development, Biorasi

12:20am
Presentation – Applying Novel Evidence Generation Techniques to Digital Therapeutics Development

Speaker to be confirmed, IQVIA

12:45pm
Lunch & Networking
2:00pm
Fireside Chat and Open Q&A – Integration of Digital Therapeutics in Novartis/Sandoz

Andre Heeg, Head of Digital, Sandoz
Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis

2:45pm
Panel – Pharma and DTx Partnerships – A Match Made in Heaven?

Spencer Jones, Vice President, Global Medical Affairs, Sandoz
Bozidar Jovecevic, Vice President, Global Head of Digital Therapeutics, Sanofi
Georgia Misti, Senior Director, Frontier Business, Sunovion Pharmaceuticals

2:00pm
Panel – What Level of Clinical Evidence is Required for Digital Therapeutics?

Anil Jina, Chief Medical Officer, Akili Interactive
Jo Masterson, Chief Product Officer, 2Morrow Inc
Acacia Parks, Chief Scientist, Happify Health

2:45pm
Panel – Providers Perspectives: How do Digital Therapeutics need to Adapt to Fit into Healthcare Systems?

Yvonne Yu-Feng Chan, Director, Center for Digital Health, Icahn School of Medicine at Mount Sinai
Dan Henderson, Primary Care Physician, Massachusetts General Hospital
Tami Smith, Head of Medical Affairs, Pear Therapeutics

3:30pm,
Afternoon Refreshments & Networking
4:00pm
Panel – What Should the Infrastructure Look like to get Digital Therapeutics to Patients?

Timothy Aungst, Associate Professor, Pharmacy Practice, MCPHS University
Crystal Broj, Chief Technology & Digital Officer, American Association of Diabetes Educators
Patricia Simon, Director, Innovation Impact, Yale School of Medicine

4:45pm
Panel – Digital Therapeutics Commercialization: Lessons Learned from the Front Line

Peter Hames, Co-Founder & Chief Executive Officer, Big Health
Debra Reisenthel, Founding Chief Executive Officer, Palo Alto Health Sciences
Carlos Rodarte, SVP Life Science Strategy & Business Development, HealthCatalyst
Brent Vaughan, Chief Executive Officer, Cognoa

4:00pm
Presentation – Voice-based Technology – The Next Generation of Digital Medicine?

Jim Harper, Co-Founder & Chief Operating Officer, Sonde Health

4:25pm
Panel – What do Digital Therapeutic Companies Need to Demonstrate when Looking to Secure Investment?

Pavan Choski, Investment Associate, Arkitekt Ventures
Shaan Gandhi, Principal, Longwood Fund
Chihiro Hosoya, BD / VC Head, Rx+ Business Accelerator, Astellas Venture Management
Zack Lynch, Managing Partner, JAZZ Venture Partners

5:30pm
Drinks Reception
Download Agenda
Day 3: September 26th
8.00 am
Breakfast & Networking
9:00pm
Chair’s Opening Remarks

Adam Kaufman, Chief Executive Officer, Canary Health

9:10am
Presentation – 8 Weeks, 4 Consultants, 1 Company: Insights and Results from the DTx East Slingshot

Michael Lieberman, PhD, Senior Vice President, Medical Sciences, Klick Consulting
Jennifer White, Senior Vice President, Strategic Partnerships, Klick Consulting

Reimbursing and Scaling Digital Therapeutics
9:35
Panel – The Reimbursement Landscape for Digital Therapeutics

Moderator: Pierre Leurent, Chief Executive Officer, Voluntis
Mark Bini, Vice President, New Solutions, Express Scripts
Sukanya Soderland, Chief Strategy Officer, Blue Cross Blue Shield Massachusetts
Matthew Tucker, Executive Director, Strategy & Transformation, Highmark Health

10:20pm
Panel – The Digital Therapeutics Engagement Chain

Moderator: Anand Iyer, Chief Strategy Officer, Welldoc
Anton Decker, President, Health Innovation, Bon Secours Mercy
Scott DeMario, HR Benefits Consultant, CUNA Mutual Group
Tammi Grumski, Diabetes Program Director, UPMC Health Plan
Dan Henderson, Primary Care Physician, Massachusetts General Hospital
Kristine Seymour, Partner, Michael Best Strategies

11:05pm
Morning Refreshments & Networking
Digital Therapeutics Showcase
11:30pm
Presentation – How to Build and Scale Digital Therapeutics in Emerging Markets

Abhishek Shah, Co-Founder & Chief Executive Officer, Wellthy Therapeutics

11:55pm
Presentation – The Role of Digital Therapeutics in the Consumerization of Health

Erez Raphael, Chief Executive Officer, Dario Health

12:20pm
Presentation – Presentation by Ieso Digital Health

Andy Blackwell, Chief Scientific Officer, Ieso Digital Health

12:45pm
Lunch & Networking
2:00pm
Panel – What do we do Great and What do we Need to Get Better at as an Industry?

Mette Dyhrberg, Founder & Chief Executive Officer, Mymee
Owen McCarthy, Co-Founder & President, MedRhythms
Pablo Pantaleoni, Vice President & General Manager, Headspace

2:45pm
Chair’s Summary

Adam Kaufman, Chief Executive Officer, Canary Health

2:50pm
Close of DTx East 2019
Download Agenda

Partnerships

The DTx summits are the home for the key decision makers in the rapidly growing Digital Therapeutics industry to meet, learn and connect.

All of the relevant companies are represented, from pioneers such as Akili, Pear and Dthera to big pharma including Sanofi, Novartis and Sandoz.

DTx East is the 5th event in the series, and the second time we are hosting the event in Boston, MA.  The programme is bigger and better than ever before, spanning 3 days.

7 Sponsors and supporters are already confirmed at launch and we have a limited number of spaces left for forward-thinking companies who want to get involved with this senior-level audience.

To discuss options available, or to learn more about the event please get in touch.

Contact Us +
Partnerships

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration